Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer
- PMID: 18698040
- DOI: 10.1158/1078-0432.CCR-08-0133
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer
Abstract
Purpose: The major value of prognostic markers in potentially curable non-small cell lung cancer (NSCLC) should be to guide therapy after surgical resection. In this regard, the patients' immune status at the time of resection may be important and also measurable. The immune system has paradoxical roles during cancer development. However, the prognostic significance of tumor-infiltrating lymphocytes is controversial. The aim of this study is to elucidate the prognostic significance of epithelial and stromal lymphocyte infiltration in NSCLC.
Experimental design: Tissue microarrays from 335 resected NSCLC, stage I to IIIA were constructed from duplicate cores of viable and representative neoplastic epithelial and stromal areas. Immunohistochemistry was used to evaluate the epithelial and stromal CD4+, CD8+, and CD20+ lymphocytes.
Results: In univariate analyses, increasing numbers of epithelial CD8+ (P = 0.023), stromal CD8+ (P = 0.002), epithelial CD20+ (P = 0.023), stromal CD20+ (P < 0.001), and stromal CD4+ (P < 0.001) lymphocytes correlated significantly with an improved disease-specific survival. No such relation was noted for epithelial CD4+ cells. Furthermore, a low level of stromal CD8+ lymphocyte infiltration was associated with an increased incidence of angiolymphatic invasion (P = 0.032). In multivariate analyses, a high number of stromal CD8+ (P = 0.043) and CD4+ (P = 0.002) cells were independent positive prognostic factors for disease-specific survival.
Conclusions: High densities of CD4+ and CD8+ lymphocytes in the stroma are independent positive prognostic indicators for resected NSCLC patients. This may suggest that these cells are mediating a strong antitumor immune response in NSCLC.
Similar articles
-
The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma.APMIS. 2010 May;118(5):371-82. doi: 10.1111/j.1600-0463.2010.02609.x. APMIS. 2010. PMID: 20477813
-
The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma.Histopathology. 2009 Sep;55(3):301-12. doi: 10.1111/j.1365-2559.2009.03379.x. Histopathology. 2009. PMID: 19723145
-
Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.Cancer. 2008 Sep 15;113(6):1387-95. doi: 10.1002/cncr.23712. Cancer. 2008. PMID: 18671239
-
[Prognostic value of CD4+ pleural cavity lymphocytes in non-small cell lung cancer].Nihon Rinsho. 2002 May;60 Suppl 5:272-5. Nihon Rinsho. 2002. PMID: 12101671 Review. Japanese. No abstract available.
-
Inflammatory cell infiltration of tumors: Jekyll or Hyde.Cancer Metastasis Rev. 2007 Dec;26(3-4):373-400. doi: 10.1007/s10555-007-9072-0. Cancer Metastasis Rev. 2007. PMID: 17717638 Review.
Cited by
-
Identification of an Immune Gene Signature Based on Tumor Microenvironment Characteristics in Colon Adenocarcinoma.Cell Transplant. 2021 Jan-Dec;30:9636897211001314. doi: 10.1177/09636897211001314. Cell Transplant. 2021. PMID: 33787354 Free PMC article.
-
High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator.Oncoimmunology. 2012 Jan 1;1(1):75-77. doi: 10.4161/onci.1.1.17825. Oncoimmunology. 2012. PMID: 22720216 Free PMC article.
-
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.J Cancer. 2020 Aug 25;11(20):6101-6113. doi: 10.7150/jca.46902. eCollection 2020. J Cancer. 2020. PMID: 32922550 Free PMC article.
-
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.J Clin Oncol. 2013 Feb 1;31(4):490-8. doi: 10.1200/JCO.2012.45.2052. Epub 2012 Dec 26. J Clin Oncol. 2013. PMID: 23269987 Free PMC article.
-
The immune response in cancer: from immunology to pathology to immunotherapy.Virchows Arch. 2015 Aug;467(2):127-35. doi: 10.1007/s00428-015-1787-7. Epub 2015 Jun 16. Virchows Arch. 2015. PMID: 26077464 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials